This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Acute lymphoblastic leukemia

Authoring team

Acute lymphoblastic leukaemia (ALL) also referred to as acute lymphocytic leukaemia, is a primary neoplasm of the bone marrow.

  • the malignant cells are the lymphocyte precursor cells (immature lymphoid blast cells - lymphoblasts) (1)
  • there is accumulation of lymphoblasts (in the marrow or various extramedullary sites) and also frequent suppression of normal haematopoiesis (2)
  • both B-cell and T-cell lymphoblasts may be responsible for ALL (1)
  • it is primarily a disease of children and young adults but can occur at any age (2)

The Philadelphia chromosome (Ph1) is seen in around 20% of adults and in a small percentage children with ALL (when compared to acute myeloid leukaemia where Ph1 occurs in only 1% to 2% of patients) (2). In Philadelphia chromosome positive ALL patients:

  • usually presents with higher white blood cell and blast counts (3)
  • children and adults who are sufficiently fit and have a well-matched donor, the most appropriate therapy is myeloablative allogeneic hematopoietic stem cell transplantation (HSCT) (4)

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.